CA3093568C - Polytherapie de cancers chimioresistants - Google Patents

Polytherapie de cancers chimioresistants

Info

Publication number
CA3093568C
CA3093568C CA3093568A CA3093568A CA3093568C CA 3093568 C CA3093568 C CA 3093568C CA 3093568 A CA3093568 A CA 3093568A CA 3093568 A CA3093568 A CA 3093568A CA 3093568 C CA3093568 C CA 3093568C
Authority
CA
Canada
Prior art keywords
cancer
antibody
ror
cells
ror1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3093568A
Other languages
English (en)
Other versions
CA3093568A1 (fr
Inventor
Thomas Kipps
Suping Zhang
Emanuela M. GHIA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority claimed from PCT/US2019/021694 external-priority patent/WO2019173843A1/fr
Publication of CA3093568A1 publication Critical patent/CA3093568A1/fr
Application granted granted Critical
Publication of CA3093568C publication Critical patent/CA3093568C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne, entre autres, des compositions et des méthodes pour le traitement d'un cancer chimiorésistant (cancer du sein). Lesdites méthodes consistent à administrer à un sujet qui en a besoin une quantité thérapeutiquement efficace d'un agent chimiothérapeutique et d'un antagoniste de ROR-1. L'invention concerne en outre des compositions pharmaceutiques comprenant un agent chimiothérapeutique, un antagoniste de ROR-1 et un excipient pharmaceutiquement acceptable. Dans certains modes de réalisation, l'agent chimiothérapeutique est paclitaxel et l'antagoniste de ROR-1 est le cirmtuzumab.
CA3093568A 2018-03-09 2019-03-11 Polytherapie de cancers chimioresistants Active CA3093568C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641035P 2018-03-09 2018-03-09
US62/641,035 2018-03-09
PCT/US2019/021694 WO2019173843A1 (fr) 2018-03-09 2019-03-11 Polythérapie de cancers chimiorésistants

Publications (2)

Publication Number Publication Date
CA3093568A1 CA3093568A1 (fr) 2019-09-12
CA3093568C true CA3093568C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US11505523B2 (en) HDAC8 inhibitors for treating cancer
CN111565722A (zh) 用于癌症治疗的腺苷路径抑制剂
US20240117047A1 (en) Monoclonal antibodies specific for human ror1
US12576082B2 (en) METTL16 inhibitors and uses thereof
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
US20240400686A1 (en) Anti-cd3 antibodies and uses thereof
US20210023238A1 (en) Triptolide antibody conjugates
US20250353924A1 (en) Anti-cd84 antibodies and uses thereof
US11739121B2 (en) EPHA2 agonists and uses thereof
US20200261462A1 (en) Combination therapy for cancer treatment
US20240415883A1 (en) Treatment of neuroendocrine cancers
CA3093568C (fr) Polytherapie de cancers chimioresistants
US20230127630A1 (en) Igf2bp2 inhibitors and uses thereof
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
US12617845B2 (en) SMC1A antibodies and uses thereof
US20250361315A1 (en) Humanized anti-cd84 recombinant protein compositions
US20230340089A1 (en) Smc1a antibodies and uses thereof
US20230255934A1 (en) Nurr1 receptor modulators and uses thereof
WO2025235952A1 (fr) Anticorps anti-cd84 humanisés
WO2026055159A1 (fr) Théranostiques tgf-bêta et leur utilisation
HK40046118A (en) Combination treatment of chemoresistant cancers
WO2022055940A1 (fr) Inhibiteurs de vista
WO2022197866A1 (fr) Anticorps anti-hvem
TW202315894A (zh) 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途